Format

Send to

Choose Destination
Clin Chim Acta. 2010 Feb;411(3-4):267-9. doi: 10.1016/j.cca.2009.11.020. Epub 2009 Nov 27.

Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.

Author information

1
Department of Pharmacology, Osaka Medical College, Takatsuki 569-8686, Japan.

Abstract

BACKGROUND:

Matrix metalloproteinase (MMP)-9 is thought to be involved in coronary artery aneurysms (CAAs) in patients with Kawasaki disease (KD); however, MMP-9 inhibitors are not used clinically. This study investigated whether the angiotensin-converting enzyme (ACE) inhibitor captopril could inhibit serum MMP-9 activity using serum from KD patients in an in vitro experiment.

METHODS:

In 7 KD patients, serum MMP-9 activity was measured using the MMP-9 assay kit 3 times: before and after intravenous immunoglobulin (IVIG) treatment, and during the convalescent phase. The effect of captopril on MMP-9 activity was also assessed using serum obtained before IVIG treatment.

RESULTS:

Serum MMP-9 activity was significantly higher during the pre-treatment phase than during the post-treatment and convalescent phases. MMP-9 activity during the pre-treatment phase was dose-dependently inhibited by captopril, and the IC(50) for MMP-9 was 500nM. The potency of captopril for MMP-9 inhibition was comparable to that for ACE inhibition.

CONCLUSION:

ACE inhibitor may be effective for preventing CAA formation in KD patients, especially IVIG non-responders.

PMID:
19945447
DOI:
10.1016/j.cca.2009.11.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center